The administration of ustekinumab increased markedly, from 133 patients in 2017 (0.5% of all IBD patients and 3.2% of patients receiving biologics) to 2001 in 2023 (4.8% of all IBD patients and 20% of patients receiving biologics), establishing it as the second most used treatment after anti-TNF agents. The gene discussed is TNF; the disease is inflammatory bowel disease.